Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 3,701–3,800 of 4,628
Diagnostic difficulty in idiopathic pulmonary fibrosis
Kondoh, Y. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.03.012 · Cited by 1
Braun, C. M., Girtman, M. A., Jenson, P. E., Bourne, M. H., Chae, J., Kottom, T. J., & LIMPER, A. H. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.29.178061 · Cited by 1
A proteomics workflow reveals predictive autoantigens in idiopathic pulmonary fibrosisPreprint
Leuschner, G., Mayr, C. H., Ansari, M., Seeliger, B., Frankenberger, M., Kneidinger, N., Hatz, R. A., Hilgendorff, A., Prasse, A., Behr, J., et al. (2021) · medRxiv · doi:10.1101/2021.02.17.21251826 · Cited by 1
Chronic Obstructive Pulmonary Disease Combined With Interstitial Lung DiseasePreprint
Choi, J. Y., Song, J. W., & Rhee, C. K. (2021) · Preprints.org · doi:10.20944/preprints202105.0083.v1 · Cited by 1
On the possibilities of colliding winds and accretion from stellar winds
Zamanov, R. K. (1993) · Observatory · Cited by 1
Ahangari, F., Becker, C., Foster, D. G., Chioccioli, M., Nelson, M., Beke, K. M., Wang, X., Readhead, B. P., Meador, C., Correll, K. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.04.474955 · Cited by 1
Pemafibrate Attenuates Pulmonary Fibrosis by Inhibiting Myofibroblast DifferentiationPreprint
Liu, Y., Chen, S., Yu, L., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4020792 · Cited by 1
Editorial: Mechanisms of Lung Fibrosis: Is Immunity Back in the Game?
Froidure, A., Antoniou, K. M., Bocchino, M., & Conte, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.882979 · Cited by 1
“nintedanib and pirfenidone, has improved the clinical management of IPF patients slowing disease progression and preventing both AEs and hospitalization (5, 6).”
BackgroundCho, K., Kim, K., Ham, S., Yun, J., Lee, S. M., Seo, J.-B., & Kim, N. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4058016 · Cited by 1
Scleroderma Associated Interstitial Lung Disease
Castelino, F. V., & Steen, V. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00016-0 · Cited by 1
Morisset, J., & Ley, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00054-8 · Cited by 1
Forrest, I., & Bourke, A.-M. (2019) · Springer eBooks · doi:10.1007/978-3-030-18944-0_9 · Cited by 1
Dimmock, A. E. F., Chuang, C. H., Hwang, W., Lehmann, H. P., Danoff, S. K., & Bascom, R. (2022) · Research Square · doi:10.21203/rs.3.rs-2008034/v1 · Cited by 1
Heymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., Nilsson, M. B., & Guijarro, I. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017.pub2 · Cited by 2
IL-11 disrupts alveolar epithelial progenitor functionPreprint
Kortekaas, R. K., Geillinger‐Kästle, K. E., Borghuis, T., Belharch, K., Webster, M. J., Timens, W., Burgess, J. K., & Gosens, R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.11.516088 · Cited by 1
The human pathome shows sex specific aging patterns post-developmentPreprint
Ezra, M. B., Garbrecht, J. B., Rasmussen, N., Heckenbach, I., Petr, M. A., Bakula, D., Mortensen, L. H., & Scheibye‐Knudsen, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.27.530179 · Cited by 3
Zhao, R., Xie, B., Wang, X., Zhang, X., Ren, Y., Dai, H., & Wang, C. (2023) · Research Square · doi:10.21203/rs.3.rs-2787815/v1 · Cited by 1
The human pathome shows sex and tissue specific aging patternsPreprint
Scheibye‐Knudsen, M., Ezra, M. B., Garbrecht, J. B., Rasmussen, N., Heckenbach, I., Petr, M. A., Bakula, D., & Mortensen, L. H. (2023) · Research Square · doi:10.21203/rs.3.rs-2652110/v1 · Cited by 1
SGLT-2 Inhibitors as Novel Treatments of Multiple Organ FibrosisPreprint
Hu, J.-P., Hui, S., Teng, J., & Liang, L. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4680858 · Cited by 1
A protective role for B-1 cells and oxidation-specific epitope IgM in lung fibrosisPreprint
Sturek, J. M., Hannan, R. T., Upadhye, A., Otoupalova, E., Faron, E. T., Atya, A. A. E., Thomas, C., Johnson, V., Miller, A., Garmey, J. C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.11.589137 · Cited by 1
Morisset, J. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.03.041 · Cited by 1
LAPTM4B Alleviates Pulmonary Fibrosis by Enhancing NEDD4L-Mediated TGF-β Signaling SuppressionPreprint
Xu, K., Pan, X., Lian, H., Wang, Y., Wan, R., Li, Z., Pan, X., Li, Y., Yang, J., Rosas, I. O., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.30.610429 · Cited by 1
Wang, R., Zhu, M., Lin, C., Gao, M., Liu, Y., & Cheng, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-4957398/v1 · Cited by 1
The role of GPR87 in Pulmonary FibrosisPreprint
Khoury, J., Ahangari, F., Adams, T. S., Justet, A., Manning, E. P., McDonough, J. E., Bärnthaler, T., Anderson, S., Nikola, F., Beermann, M. L., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.10.617569 · Cited by 1
Elastokines are Associated with a Poor Prognosis in Idiopathic Pulmonary FibrosisPreprint
Nagel, D. J., Okutani, T., Lopa, S., et al. (2025) · medRxiv · doi:10.1101/2025.06.06.25327886 · Cited by 1
Controlled decorin delivery from injectable microgels promotes scarless vocal fold repairPreprint
Friedman, R. M., Brown, E. A., Bonelli, H. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.25.661429 · Cited by 1
Zhang, X., Liu, X., Qiao, Y., Rabata, A., Liu, N., Yao, C., Parimon, T., Chen, D., Chen, P., Stripp, B. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.30.662456 · Cited by 1
Self-citationOtoupalova, E., Hannan, R. T., Raichura, P., Batrash, N., Dell, P., Rodrigues‐Jesus, M. J., Zunder, E. R., Wilson, J. M., Woodfolk, J. A., Taylor, J. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.11.28.691061 · Cited by 1
Therapie der idiopathischen Lungenfibrose
Schreiber, J. (2014) · Der Pneumologe · doi:10.1007/s10405-014-0819-3
Transbronchial cryobiopsy in diffuse parenchymal lung disease
Ussavarungsi, K., Patel, N. M., & Lee, A. S. (2015) · DOAJ (DOAJ: Directory of Open Access Journals)
Fibrosis pulmonar idiopática. Con el blanco en la mira
Otaola, M. (2014) · Redalyc (Universidad Autónoma del Estado de México)
Role of Progenitors in Pulmonary Fibrosis and Asthma
Banerjee, E. R. (2014) · Springer eBooks · doi:10.1007/978-81-322-2053-4_8
Vij, R., Denton, C. P., & Noth, I. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0751ed
Duffield, J. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800102-8.00023-0
Update on New Treatments for Idiopathic Pulmonary Fibrosis
DeGrado, J. R., & Gilmore, J. F. (2015) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-015-0076-8
Reply: Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials?
Richeldi, L., Maulf, F. L., Schlenker‐Herceg, R., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201507-1354le
Self-citationGoyard, C., & Cottin, V. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(15)30038-0
Self-citationManagement of Scleroderma-Associated Pulmonary Involvement
Dobrota, R., Distler, O., Wells, A. U., & Humbert, M. J. C. (2015) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-014-0011-2
Evaluación positiva de medicamentos: septiembre/octubre/noviembre 2014
Tabakov, A., Hernández, R. A., Morán, M. J. P., et al. (2015) · Sanidad militar: revista de sanidad de las Fuerzas Armadas de España · doi:10.4321/s1887-85712015000100007
Idiopathische pulmonale Fibrose
Markart, P., Wygrecka, M., & Günther, A. (2015) · Pneumo News · doi:10.1007/s15033-014-0003-9
Ancochea, J., Pérez, T. A., Gutiérrez, M. D. V. S., & Valenzuela, C. (2014) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(14)70847-9
Enfermedades pulmonares intersticiales difusas. Neumoconiosis. Neumonitis por hipersensibilidad
Pérez, T. A., Valenzuela, C., Moreno, R. M. G., et al. (2014) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(14)70846-7
Kärperliches Training sollte zur Therapie gehären
Schultz, K. (2015) · Pneumo News · doi:10.1007/s15033-015-0092-0
An Efficient Inter-Coding Algorithm For H.264
Aslam, L., & Khan, N. A. (2007) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.40460
Hope for Disease-Modifying Treatment of Systemic Sclerosis/Scleroderma
Michel, M. C. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213520comm
Fibrosis pulmonar idiopática: retos en el diagnóstico y ventajas de un abordaje multidisciplinar
Portal, J. A. R. (2015) · Monografías de Archivos de Bronconeumología
Treatment of lymphangioleiomyomatosis and Camões
Rufino, R. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000400001
Tratamiento de la fibrosis pulmonar idiopática: de la teoría a la vida real
Nieto, A., & Valenzuela, C. (2015) · Monografías de Archivos de Bronconeumología
“The Long and Winding Road” seeking specific drugs for idiopathic pulmonary fibrosis
Munakata, M. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.12.001
Pharmacotherapy of IPF (Corticosteroids, Immunosuppressants, Etc.)
Bando, M. (2015) · Springer eBooks · doi:10.1007/978-4-431-55582-7_10
Itoh, M. (2015) · Springer eBooks · doi:10.1007/978-4-431-55582-7_12
Traitement médical de la fibrose pulmonaire idiopathique : de nouvelles perspectives
Bouvry, D., & Jouneau, S. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70619-6
Fibrose pulmonaire idiopathique : une nouvelle ère, de nouveaux défis
Cottin, V. (2014) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2014.07.009
Self-citationVerlust der Lungenfunktion gebremst
Klein, F. (2015) · Pneumo News · doi:10.1007/s15033-015-0115-x
Idiopathische Lungenfibrose wird erstmals behandelbar
Einecke, D. (2015) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-015-2632-2
3) Pulmonary Fibrosis and Its Management
Azuma, A. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.105b
Self-citationTyrosinkinase-Inhibitor bremst Progression
Einecke, D. (2015) · Pneumo News · doi:10.1007/s15033-015-0085-z
3. Diagnosis and Therapy of Interstitial Pneumonias-Up to Date-
Ogura, T. (2015) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.104.546
Neue Empfehlungen bei idiopathischer Lungenfibrose
Markart, P., & Gesierich, W. (2015) · Pneumo News · doi:10.1007/s15033-015-0214-8
Do New Drugs Meet the Expectations in the Treatment of Idiopathic Pulmonary Fibrosis?
Okutan, O., & Ayten, Ö. (2016) · Eurasian Journal of Pulmonology · doi:10.5152/ejp.2016.55376
Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension
Huston, J., Hatton, N. D., & Ryan, J. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-23594-3_3
Directed Differentiation of Human Pluripotent Stem Cells into Lung and Airway Epithelial Cells
Snoeck, H. (2015) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-21082-7_16
Koyama, N. (2015) · Springer eBooks · doi:10.1007/978-4-431-55582-7_14
Ishii, Y. (2015) · Springer eBooks · doi:10.1007/978-4-431-55582-7_3
3e Journée française de la fibrose pulmonaire idiopathique. 19 septembre 2014
Cottin, V., Crestani, B., Danel, C. J., Debray, M., Nunès, H., Poletti, V. E., Prévost, G., Vergnon, J.-M., Wallaert, B., & Cordier, J. F. (2015) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2015.06.002
Self-citationIdiopathic lung fibrosis in an adult Ecuadorian from Riobamba province
Jesús, O. D., Hayes, C., & de Girón, P. V. (2016)
New Insights on Mechanisms and Treatment in Idiopathic Pulmonary Fibrosis
Ciobanu, L. D. (2016) · Global Journal of Respiratory Care · doi:10.12974/2312-5470.2016.03.2
Idiopathic interstitial pneumonias
Olivieri, D., Chiesa, S., & Tzani, P. (2013) · European Respiratory Society eBooks · doi:10.1183/9781849840415.007012
Maher, T. M., & Spagnolo, P. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006615 · Cited by 1
ADVANCES IN THERAPIES FOR INTERSTITIAL LUNG DISEASES
Ferrara, G., & Sköld, M. C. (2015) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814656337_0012
Grundlagen der medikamentösen Therapie
Drakopanagiotakis, F., & Günther, A. (2016) · Springer eBooks · doi:10.1007/978-3-662-48419-7_5
Key ongoing issues in trial design
Jones, M. G., & Richeldi, L. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006515
Self-citationValeyre, D., Jeny, F., Freynet, O., & Nunès, H. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10004915 · Cited by 1
Chisholm, A., Eid, N. S., Navarrete, B. A., et al. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.07.16
Symptom management: dyspnoea and cough
Wuyts, W. A. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006215
Potential Mechanistic Links Between Aging and IPF
Pan, H., Gulati, M., & Herzog, E. L. (2015) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814635011_0016
A New Era in the Treatment of Scleroderma-associated Interstitial Lung Disease?
Launay, D. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.160887
Death Receptors 4 and 5 and Idiopathic Pulmonary Fibrosis
Miller, S. (2016) · University of Minnesota Digital Conservancy (University of Minnesota)
Wirksamkeit von Nintedanib bei verschiedenen IPF-Subgruppen vergleichbar
Markart, P., & Günther, A. (2016) · Pneumo News · doi:10.1007/s15033-016-0436-4
Liu, D., & Huang, G. (2016) · Journal of Clinical & Experimental Pathology · doi:10.4172/2161-0681.1000289
Nintedanib for idiopathic pulmonary fibrosis: A n A sian perspective
Chambers, D. C. (2016) · Respirology · doi:10.1111/resp.12903
Tyrosinkinasehemmer bei IPF auch ohne UIP-Muster im Lungen-CT wirksam
Markart, P., & Günther, A. (2016) · Pneumo News · doi:10.1007/s15033-016-0486-7
Rubin, A. S., Nascimento, D. Z., Sánchez-Valdeón, L., et al. (2015)
Neue Erkenntnisse zur Pathogenese des akuten Atemnotsyndroms
Sharp, C., Millar, A., & Medford, A. R. L. (2016) · Kompass Pneumologie · doi:10.1159/000448770
Pirfenidon plus Nintedanib bei idiopathischer pulmonaler Fibrose
Drakopanagiotakis, F. (2016) · Kompass Pneumologie · doi:10.1159/000448780
Nintedanib bietet Wirksamkeit und Sicherheit – auch in der Langzeittherapie
Jäger-Becker, D. (2016) · Pneumo News · doi:10.1007/s15033-016-0551-2
Risikofaktoren für akute Exazerbationen der IPF
Markart, P., & Günther, A. (2016) · Pneumo News · doi:10.1007/s15033-016-0526-3
Progressive Interstitial Lung Disease Nonresponse to Cyclophosphamide
Silver, K., Highland, K. B., & Silver, R. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_55
Die idiopathische Lungenfibrose Idiopathic Pulmonary Fibrosis
Prasse, A., Pneumologie, A., Item, F., et al. (2015)
Reference values for forced vital capacity in idiopathic pulmonary fibrosis
Pereira, C. A. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.11.022
Exacerbation aiguë d’une fibrose pulmonaire idiopathique
Dacosta-Noble, P., & Naccache, J. (2016) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30073-8
Mission CPLF 2016 : les pneumopathies interstitielles à l’honneur !
Sanchez, O. (2016) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30086-6
Acute exacerbations of interstitial lung disease
Veltkamp, M., & Grutters, J. C. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10001816
Reply: Is a Trial of Vitamin K Antagonists and Bisphosphonates Possible in IPF?
Margaritopoulos, G. A., & Antoniou, K. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201608-1636le · Cited by 1
Pneumopathies interstitielles diffuses
Wémeau-Stervinou, L. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(15)30078-1
Bouvry, D., & Jouneau, S. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(15)30063-x
Idiopathic pulmonary fibrosis - or what new in idiopathic interstitial pneumonia
Doubková, M. (2016) · Interní medicína pro praxi · doi:10.36290/int.2016.015
Lung Cancer Complicated with Interstitial Lung Diseases
Minegishi, Y. (2017) · Springer eBooks · doi:10.1007/978-981-10-2002-5_15
Fibrose pulmonaire idiopathique: le point sur l'imagerie tomodensitométrique
Brillet, P. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(15)30065-3
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.